WINSTON-SALEM, North Carolina, February 14, 2022 /PRNewswire/ — Javara, a leading integrated research organization focused on providing access to clinical trials at the point of care, today announced an opportunity for adults age 60 or older who live in the Fayetteville, Georgia; Annapolis, Maryland; Where Fort Worth, TX regions to participate in a clinical trial of an experimental new vaccine aimed at protecting them from respiratory syncytial virus (RSV). This clinical trial is launched in partnership with certain Privia Health Group (Nasdaq: PRVA) subsidiaries and affiliates.
Many know RSV as a seasonal illness that affects infants, but don’t realize that the virus also frequently causes severe acute respiratory illness in the elderly. Each year in the United States, more than 177,000 people age 65 or older are hospitalized with RSV, and approximately 14,000 of them die from the virus.1 Additionally, treating RSV in the elderly generates approximately $3 billion in annual medical costs nationwide. Because of these concerns, prevention of RSV in the elderly is of urgent public health importance, but there are no approved preventive vaccines available.
In stage 2/3 ConquerRSV Clinical Trialbiotechnology company Moderna, Inc. (Nasdaq: mRNA) is evaluating the safety and efficacy of its investigational mRNA-1345 vaccine in preventing RSV symptoms in the elderly. It is hoped that this experimental vaccine will first prepare the immune system to recognize the virus by identifying the presence of the RSV F-glycoprotein, and then to fight the virus by generating neutralizing antibodies. Since the experimental vaccine does not use a weakened or inactivated form of RSV, mRNA-1345 cannot cause RSV infection.
Javara, together with its healthcare partners, is working to ensure that communities and patients have access to cutting-edge developments while enabling the diverse representation that is essential in the scientific evaluation of this candidate vaccine.
“Second to the flu in causing significant respiratory disease in adults,3 RSV represents an often unrecognized but very real and imminent threat to our elderly population. Being able to get vaccinated against this virus could save lives, prevent hospitalizations and conserve healthcare resources,” said Javara’s chief operating officer, Michael Clay. “By taking this opportunity to test an experimental vaccine aimed at preventing RSV, older adults can increase the possibility of being protected from the discomforts and dangers of this virus. At the same time, by helping to advance this research, these trials participants will do their part to prevent suffering and save lives around the world.”
Clinical Director of Privia Health Keith FernandezMD said, “We are proud to offer Privia patients the opportunity to participate in this clinical trial. This new RSV vaccine candidate has significant potential to improve the health of our aging population and reduce unnecessary costs within our healthcare system — two key components of Privia’s mission to deliver high-quality, at low cost to patients. »
The ConquerRSV trial will recruit approximately 34,000 participants in good general health. Participants will receive either mRNA-1345 or a placebo. Those interested in participating can contact one of the following places:
- Older people are at high risk of severe RSV infection. Centers for Disease Control website. https://www.cdc.gov/rsv/factsheet-older-adults.pdf. Posted August 2017. Accessed November 3, 2021.
- mRNA-1345 vaccine against respiratory syncytial virus (RSV). Precision Vaccinations website. https://www.precisionvaccinations.com/vaccines/mrna-1345-respiratory-syncytial-virus-rsv-vaccine. Update December 1, 2021. Accessed December 14, 2021.
- Falsey AR, Walsh EE. Respiratory syncytial virus infection in the elderly. Aging Drugs. 2005;22:577-587.
Javara, the leading integrated research organization (IRO), partners with leading healthcare organizations to provide point-of-care access to clinical trials through integrated research staff and infrastructure. Our access to highly diverse patient populations through their trusted physician ensures that clinical trials are completed with high enrollment and retention rates for delivering quality data. Javara’s centralized resources and standardized operations deliver efficiencies for accelerated study start-up and quality results, so fewer obstacles stand in the way of the product approval process. As pioneers in Clinical Research as an Option for Care (CRAACO), Javara is transforming healthcare and changing lives by connecting the right patients to the right trials at the right time. For more information, please visit Javararesearch.com.
About Privia Health
Privia Health™ is a national physician enablement company that works with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward physicians for delivering care of great value in both in-person and virtual contexts. Privia partners with more than 3,250 providers in seven states and the District of Colombia, providing care to more than three million patients in more than 850 practice locations. The Privia platform is driven by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end cloud technology that reduces unnecessary healthcare costs, achieves better outcomes and improves patient health and well-being. being suppliers. For more information, visit priviahealth.com.
Javara Media Contact: